Related Experiment Video
Updated: Jun 17, 2026
09:59
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
12.4K
Review of CFTR modulators 2020
Danielle M Goetz1, Adrienne P Savant2
1Department of Pediatrics, University at Buffalo School of Medicine, New York, New York, USA.
Pediatric Pulmonology
|August 18, 2021
Summary
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators improve CFTR protein function, enhancing outcomes for people with cystic fibrosis. Research in 2020 explored new benefits, side effects, costs, and future clinical trials for these vital therapies.
Area of Science:
- Pharmacology and Therapeutics
- Pulmonology
- Genetics
Background:
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a class of drugs that target the underlying cause of cystic fibrosis by improving the function of the defective CFTR protein.
- Since the FDA approval of ivacaftor in 2012, CFTR modulators have demonstrated significant positive impacts on clinical outcomes for people with cystic fibrosis (PwCF).
- Ongoing research continues to expand the understanding and application of CFTR modulators beyond initial findings.
Purpose of the Study:
- To review the latest research on CFTR modulators published in 2020, focusing on advancements in understanding their clinical impact.
- To synthesize new insights into novel outcomes, adverse effects, cost considerations, and future directions for clinical trials involving CFTR modulators.
- To provide the cystic fibrosis community with an updated overview of developments in CFTR modulator research.
Main Methods:
- Systematic review of articles on CFTR modulators published in 2020, with a primary focus on Pediatric Pulmonology.
- Inclusion of relevant articles from other journals of significant interest to clinicians treating cystic fibrosis.
- Analysis of research encompassing clinical insights, novel outcomes, adverse effects, cost, and future trial designs.
Main Results:
- CFTR modulator research in 2020 revealed continued progress in improving lung function, growth, and other clinical parameters in PwCF.
- New studies investigated a broader range of outcomes, including previously unrecognized benefits and potential adverse effects associated with these therapies.
- The review highlighted ongoing discussions regarding the cost-effectiveness and accessibility of CFTR modulators, alongside strategic planning for upcoming clinical trials.
Conclusions:
- CFTR modulators represent a significant therapeutic advancement for cystic fibrosis, with ongoing research continually refining their use and understanding.
- The 2020 research landscape demonstrates a deepening comprehension of CFTR modulator efficacy, safety, and economic implications.
- Continued investigation and clinical trials are essential to further optimize the benefits of CFTR modulators and improve long-term care for all people with cystic fibrosis.
Keywords:
cystic fibrosiscystic fibrosis transmembrane regulator (CFTR) modulatorspulmonologytreatmentMore Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.6K
06:59A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
Published on: June 22, 2022
2.3K
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).